The role of immunity to EBV in the development of MS

Professor Michael Pender

The University of Queensland, QLD

| Causes and Prevention | Immunology | Project | 2010 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

A large body of epidemiological evidence indicates that infection with the Epstein-Barr virus (EBV), the causative agent of glandular fever, is essential for the development of MS. EBV is a virus that selectively infects human B cells, which are the white blood cells that produce antibodies. In healthy people the number of EBV-infected B cells is kept under strict control by the immune system. ‘Cytotoxic’ CD8+ T cells are the white blood cells that kill abnormal cells, such as EBV-infected B cells, and keep the number of these cells to a minimum.

In previous research studies, Prof Pender and colleagues have shown that people with MS have a decreased number of cytotoxic T cells capable of responding to their own EBV-infected B cells. It is thought that this decrease in the number of cytotoxic T cells might predispose people to MS by allowing the EBV-infected B cells to accumulate in the brain.

In the present project the researchers are further investigating the immune response to EBV in people with MS. In particular Prof Pender is studying two subtypes of T cells: the ‘cytotoxic’ CD8+ T cells and the ‘helper’ CD4+ T cells, which activate and direct other immune cells. Looking at these cell types’ responses to EBV will determine the cause of the decreased T cell response to EBV and its relationship to the clinical features of MS.

Project Outcomes

The project has so far examined the cytotoxic T cells in MS. Prof Pender has shown that the decreased cytotoxic T cell response to EBV in MS is due to a general deficiency of cytotoxic T cells in people with MS compared with healthy people. He found that within the total cytotoxic T cell population there was a reduced proportion of EBV-specific T cells, the cells required to kill the EBV-infected B cells. Prof Pender has been able to rule out the possibility that the reduced response of cytotoxic T cells was due to a decreased presentation of the EBV fragments to the cytotoxic T cells, one mechanism that might have explained the lower response in MS.

Prof Pender has also found that there is an accelerated age-related decline in cytotoxic T cells in people with MS compared with healthy people. Comparisons with the helper T cells in MS showed that the immune response driven by this cell type was not impaired in MS.

This work has led to an impressive six papers published in respected scientific journals (please see below). This research has the potential to lead to the development of new therapies for preventing and treating MS by controlling EBV infection, for example by vaccination or antiviral drugs. This work has also provided the foundation for a new project looking at the immune memory of EBV responsive cells in MS.

Publications

  • Pender MP (2011) The essential role of Epstein–Barr virus in the pathogenesis of multiple sclerosis. The Neuroscientist17:351–367.
  • Pender MP, Csurhes PA, Pfluger CMM, Burrows SR (2011) Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurology 11:95.
  • Pender MP (2012) Epstein–Barr virus in the multiple sclerosis brain – An evasive culprit. Multiple Sclerosis and Related Disorders 1:61–63.
  • Pender MP (2012) CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency and steps to autoimmunity: a unifying hypothesis. Autoimmune Diseases 2012:189096.
  • Pender MP, Csurhes PA, Pfluger CMM, Burrows SR (2012) CD8 T cell deficiency impairs control of Epstein–Barr virus and worsens with age in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 83:353–354.
  • Pender MP, Csurhes PA, Pfluger CMM, Burrows SR (2012) CD8+ T cells far predominate over CD4+ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood 120:5085–5087.

Updated: 12 June 2013

Updated: 06 January, 2010

Investigator

  • Professor Michael Pender, The University of Queensland, QLD
  • Associate Professor Scott Burrows, Royal Brisbane & Women’s Hospital, QLD

Grant Awarded

  • Project Grant

Total Funding

  • $390,000

Duration

  • 3 years over 2010 - 2012

Read More

Newsletter subscription

  • Enter your details

The role of immunity to EBV in the development of MS